Evidence map›Paper›PMID 42237860›Full record

ReviewEpilepsia open2026

Beyond seizures: A multidimensional approach to non-seizure issues in Lennox-Gastaut syndrome. Insights from Italian experts.

Giancarlo Di Gennaro, Domenica Immacolata Battaglia, Paolo Bonanni, Gian Marco Duma, Antonietta Coppola, Edoardo Ferlazzo, Dario Pruna, Carlo Di Bonaventura

Abstract readReview
In one paragraph

Review in Epilepsia open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Giancarlo Di GennaroIRCCS Neuromed, Pozzilli (IS), Italy.ORCID https://orcid.org/0000-0003-3446-0788
Domenica Immacolata BattagliaChild Neuropsychiatry, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy.
Paolo BonanniScientific Institute IRCCS E. Medea, Epilepsy and Clinical Neurophysiology Unit (UOC), Conegliano, Italy.
Gian Marco DumaScientific Institute IRCCS E. Medea, Epilepsy and Clinical Neurophysiology Unit (UOC), Conegliano, Italy.ORCID https://orcid.org/0000-0002-0778-3920
Antonietta CoppolaNeurology Unit and Epilepsy Center (U.O.C), Federico II University Hospital, Naples, Italy.ORCID https://orcid.org/0000-0002-4845-4293
Edoardo FerlazzoRegional Epilepsy Center/Neurology Unit (UOC), Grande Ospedale Metropolitano BMM, Reggio Calabria, Italy.
Dario PrunaPediatric Neurology and Epileptology Unit (S.S.D.), ARNAS Brotzu, Cagliari, Italy.
Carlo Di BonaventuraIRCCS Neuromed, Pozzilli (IS), Italy.ORCID https://orcid.org/0000-0003-1890-5409

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-seizure issues (NSIs), including cognition, behavior/psychiatric symptoms, adaptive and social functioning, sleep, autonomic, and motor impairments, often shape day-to-day outcomes in Lennox-Gastaut syndrome (LGS) more than seizures, yet clinicians lack LGS-specific, feasible assessment pathways. An expert panel synthesized evidence and clinical experience to propose a lifespan, clinic-ready framework that pairs clinician-administered measures with caregiver/teacher reports and uses brief global impressions from both clinicians and caregivers to detect meaningful change. The framework emphasizes continuous, structured conversations about NSIs at every visit, with standardized tools deployed less frequently in line with the properties of instrument re-administration and local resources. As a pragmatic guide, behavior/sleep are typically reviewed every 6-12 months, and cognition/adaptive skills are reviewed annually. Rather than prescribing a universal "minimum battery" the approach prioritizes personalization to developmental stage, comorbidities, disability level, and family context. The Discussion also integrates therapeutic considerations: Early data suggest fenfluramine and cannabidiol may benefit alertness, behavior, sleep, and communication beyond seizure reduction, while acknowledging that LGS-specific evidence remains preliminary. Key gaps include the limited validation of instruments in LGS, the scarcity of adult-focused measures (e.g., biopsychosocial frailty), and tools that are insufficiently sensitive to small but meaningful changes. We outline a research agenda for co-designed clinical outcome assessments that combine quantitative scales with qualitative insights from patients, caregivers, and teachers. Centering NSIs and feasible follow-up, this work offers a practical route to move LGS care beyond seizure counts toward participation, resilience, and quality of life for patients and families. PLAIN LANGUAGE SUMMARY: People with Lennox-Gastaut syndrome often struggle with problems beyond seizures, such as learning, behavior, sleep, movement, and daily living skills. These non-seizure issues can affect quality of life even more than seizure counts. We propose a practical, clinic-ready approach to check these issues across all ages using brief clinician assessments plus caregiver and teacher input. Regular conversations at each visit, with targeted questionnaires every 6-12 months or yearly, can help detect meaningful changes and guide care.

Indexed as

Lennox Gastaut SyndromeHumansSeizuresbiopsychosocial systemcaregiver burdendevelopmental and epileptic encephalopathiespatient‐centered outcomesquality of life

Identifiers

PMID42237860
PMCPMC13394045

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.